Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review

References

• Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95(6):1931–1934.
   PubMed Web of Science ®Google Scholar
• Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336(19):1365–1372.
   PubMed Web of Science ®Google Scholar
• Sakuma T, Hayashi Y, Kanomata N, et al. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes. Pathol Int. 2006;56(4):191–199.
   PubMed Web of Science ®Google Scholar
• Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res. 2009;668(1–2):4–10.
   PubMed Web of Science ®Google Scholar
• Walne AJ, Dokal I. Dyskeratosis Congenita: a historical perspective. Mech Ageing Dev. 2008;129(1–2):48–59.
   PubMed Web of Science ®Google Scholar
• Rovó A, Tichelli A, Dufour C. Diagnosis of acquired aplastic anemia. Bone Marrow Transplant. 2013;48(2):162–167.
   PubMed Web of Science ®Google Scholar
• Young NS, Maciejewski JP, Sloand E, et al. The relationship of aplastic anemia and PNH. Int J Hematol. 2002;76(Suppl 2):168–172.
   PubMed Web of Science ®Google Scholar
• Brown KE, Tisdale J, Barrett AJ, et al. Hepatitis-associated aplastic anemia. N Engl J Med. 1997;336(15):1059–1064.
   PubMed Web of Science ®Google Scholar
• Stalder MP, Rovó A, Halter J, et al. Aplastic anemia and concomitant autoimmune diseases. Ann Hematol. 2009;88(7):659–665.
   PubMed Web of Science ®Google Scholar
• Dufour C, Pillon M, Passweg J, et al. Outcome of aplastic anemia in adolescence: a survey of the severe aplastic anemia working party of the European Group for Blood and Marrow Transplantation. Haematologica. 2014;99(10):1574–1581.
   PubMed Web of Science ®Google Scholar
• Ades L, Mary J-Y, Robin M, et al. Long-term outcome after bone marrow transplantation for severe aplastic anemia. Blood. 2004;103(7):2490–2497.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Hows J, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988;70(2):177–182.
   PubMed Web of Science ®Google Scholar
• Camitta BM, Rappeport JM, Parkman R, et al. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975;45(3):355–363.
   PubMed Web of Science ®Google Scholar
• Rozman C, Marín P, Nomdedeu B, et al. Criteria for severe aplastic anaemia. Lancet. 1987;2(8565):955–957.
   PubMed Web of Science ®Google Scholar
• Catlin SN, Busque L, Gale RE, et al. The replication rate of human hematopoietic stem cells in vivo. Blood. 2011;117(17):4460–4466.
   PubMed Web of Science ®Google Scholar
• Olweus J, Lund-Johansen F, Terstappen LW. Expression of cell surface markers during differentiation of CD34+, CD38-/lo fetal and adult bone marrow cells. Immunomethods. 1994;5(3):179–188.
   PubMedGoogle Scholar
• Maciejewski JP, Anderson S, Katevas P, et al. Phenotypic and functional analysis of bone marrow progenitor cell compartment in bone marrow failure. Br J Haematol. 1994;87(2):227–234.
   PubMed Web of Science ®Google Scholar
• Sutherland HJ, Eaves CJ, Eaves AC, et al. Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood. 1989;74(5):1563–1570.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Kim S, Sloand E, et al. Sustained long-term hematologic recovery despite a marked quantitative defect in the stem cell compartment of patients with aplastic anemia after immunosuppressive therapy. Am J Hematol. 2000;65(2):123–131.
   PubMed Web of Science ®Google Scholar
• Wilson A, Laurenti E, Oser G, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135(6):1118–1129.
   PubMed Web of Science ®Google Scholar
• Sato T, Onai N, Yoshihara H, et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med. 2009;15(6):696–700.
   PubMed Web of Science ®Google Scholar
• Passegué E, Wagers AJ, Giuriato S, et al. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J Exp Med. 2005;202(11):1599–1611.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Selleri C, Sato T, et al. A severe and consistent deficit in marrow and circulating primitive hematopoietic cells (long-term culture-initiating cells) in acquired aplastic anemia. Blood. 1996;88(6):1983–1991.
   PubMed Web of Science ®Google Scholar
• Zeng W, Chen G, Kajigaya S, et al. Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood. 2004;103(1):325–332.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun Q, Morita Y, et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell. 2012;148(5):1001–1014.
   PubMed Web of Science ®Google Scholar
• Mauch P, Rosenblatt M, Hellman S. Permanent loss in stem cell self renewal capacity following stress to the marrow. Blood. 1988;72(4):1193–1196.
   PubMed Web of Science ®Google Scholar
• Shao L, Luo Y, Zhou D. Hematopoietic stem cell injury induced by ionizing radiation. Antioxid Redox Signal. 2014;20(9):1447–1462.
   PubMed Web of Science ®Google Scholar
• Malkin D, Koren G, Saunders EF. Drug-induced aplastic anemia: pathogenesis and clinical aspects. Am J Pediatr Hematol Oncol. 1990;12(4):402–410.
   PubMedGoogle Scholar
• Morinet F, Leruez-Ville M, Pillet S, et al. Concise review: anemia caused by viruses. Stem Cells. 2011;29(11):1656–1660.
   PubMed Web of Science ®Google Scholar
• Xing L, Liu C, Fu R, et al. CD8+HLA-DR+ T cells are increased in patients with severe aplastic anemia. Mol Med Rep. 2014;10(3):1252–1258.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364(9431):355–364.
   PubMed Web of Science ®Google Scholar
• Schuster FR, Hubner B, Führer M, et al. Highly skewed T-cell receptor V-beta chain repertoire in the bone marrow is associated with response to immunosuppressive drug therapy in children with very severe aplastic anemia. Blood Cancer J. 2011;1(3):e8.
   PubMed Web of Science ®Google Scholar
• Goto M, Kuribayashi K, Takahashi Y, et al. Identification of autoantibodies expressed in acquired aplastic anaemia. Br J Haematol. 2013;160(3):359–362.
   PubMed Web of Science ®Google Scholar
• Kordasti S, Marsh J, Al-Khan S, et al. Functional characterization of CD4+ T cells in aplastic anemia. Blood. 2012;119(9):2033–2043.
   PubMed Web of Science ®Google Scholar
• Kordasti S, Costantini B, Seidl T, et al. Deep-phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. Blood. 2016;128:1193–1205.
   PubMed Web of Science ®Google Scholar
• Giannakoulas NC, Karakantza M, Theodorou GL, et al. Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. Br J Haematol. 2004;124(1):97–105.
   PubMed Web of Science ®Google Scholar
• Liu C, Li Z, Sheng W, et al. Abnormalities of quantities and functions of natural killer cells in severe aplastic anemia. Immunol Invest. 2014;43(5):491–503.
   PubMed Web of Science ®Google Scholar
• Hanaoka N, Nakakuma H, Horikawa K, et al. NKG2D-mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes. Br J Haematol. 2009;146(5):538–545.
   PubMed Web of Science ®Google Scholar
• Philpott NJ, Scopes J, Marsh JC, et al. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp Hematol. 1995;23(14):1642–1648.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Selleri C, Sato T, et al. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995;91(1):245–252.
   PubMed Web of Science ®Google Scholar
• Killick SB, Cox CV, Marsh JC, et al. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol. 2000;111(4):1164–1169.
   PubMed Web of Science ®Google Scholar
• Maciejewski J, Selleri C, Anderson S, et al. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85(11):3183–3190.
   PubMed Web of Science ®Google Scholar
• Sloand E, Kim S, Maciejewski JP, et al. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100(4):1185–1191.
   PubMed Web of Science ®Google Scholar
• Dufour C, Svahn J, Bacigalupo A. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 2013;48(2):174–177.
   PubMed Web of Science ®Google Scholar
• Kakagianni T, Giannakoulas NC, Thanopoulou E, et al. A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients. Leuk Res. 2006;30(6):713–721.
   PubMed Web of Science ®Google Scholar
• Zhang J-Y, Chang H, Meng W-T. [The polymorphism of interferon gamma gene CA short tandem repeat is associated with aplastic anemia]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008;39(1):23–25, 58.
   PubMedGoogle Scholar
• Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106(6):661–673.
   PubMed Web of Science ®Google Scholar
• Brümmendorf TH, Maciejewski JP, Mak J, et al. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97(4):895–900.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Kook H, Chung IJ, et al. Telomere length changes in patients with aplastic anaemia. Br J Haematol. 2001;112(4):1025–1030.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Cooper JN, Sloand EM, et al. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. Jama. 2010;304(12):1358–1364.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med. 2005;352(14):1413–1424.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Baerlocher GM, Lansdorp PM, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood. 2003;102(3):916–918.
   PubMed Web of Science ®Google Scholar
• Houben JM, Moonen HJJ, Van Schooten FJ, et al. Telomere length assessment: biomarker of chronic oxidative stress? Free Radic Biol Med. 2008;44(3):235–246.
   PubMed Web of Science ®Google Scholar
• Dumitriu B, Feng X, Townsley DM, et al. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia. Blood. 2015;125(4):706–709.
   PubMed Web of Science ®Google Scholar
• Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011;118(25):6601–6609.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Selleri C. Evolution of clonal cytogenetic abnormalities in aplastic anemia. Leuk Lymphoma. 2004;45(3):433–440.
   PubMed Web of Science ®Google Scholar
• Maciejewski JP, Risitano A, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99(9):3129–3135.
   PubMed Web of Science ®Google Scholar
• Mikhailova N, Sessarego M, Fugazza G, et al. Cytogenetic abnormalities in patients with severe aplastic anemia. Haematologica. 1996;81(5):418–422.
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med. 2015;373(1):35–47. .
   PubMed Web of Science ®Google Scholar
• Frickhofen N, Heimpel H, Kaltwasser JP, et al. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101(4):1236–1242.
   PubMed Web of Science ®Google Scholar
• Rosenfeld S, Follmann D, Nunez O, et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. Jama. 2003;289(9):1130–1135.
   PubMed Web of Science ®Google Scholar
• Tichelli A, Schrezenmeier H, Socié G, et al. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2011;117(17):4434–4441.
   PubMed Web of Science ®Google Scholar
• Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96(6):2049–2054.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Borthakur G, Garcia-Manero G, et al. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012;157(3):312–320.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430–438. .
   PubMed Web of Science ®Google Scholar
• Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012;119(23):5391–5396.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Socié G, Hinterberger W, et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood. 1997;90(2):858–864.
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Oneto R, Bacigalupo A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11–18.
   PubMed Web of Science ®Google Scholar
• Ahn M-J, Choi J-H, Lee -Y-Y, et al. Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Int J Hematol. 2003;78(2):133–138.
   PubMed Web of Science ®Google Scholar
• Dulley FL, Vigorito AC, Aranha FJP, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transplant. 2004;33(1):9–13.
   PubMed Web of Science ®Google Scholar
• Bai LY, Chiou TJ, Liu JH, et al. Hematopoietic stem cell transplantation for severe aplastic anemia–experience of an institute in Taiwan. Ann Hematol. 2004;83(1):38–43.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Park CY, Park YH, et al. Successful allogeneic hematopoietic stem cell transplantation using triple agent immunosuppression in severe aplastic anemia patients. Bone Marrow Transplant. 2003;31(2):79–86.
   PubMed Web of Science ®Google Scholar
• Kahl C, Leisenring W, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol. 2005;130(5):747–751.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Pérez WS, Eapen M, et al. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant. 2006;37(7):641–649.
   PubMed Web of Science ®Google Scholar
• Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100(3):799–803.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, O’Donnell M, Tolar J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108(5):1485–1491.
   PubMed Web of Science ®Google Scholar
• Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53(3):504–514.
   PubMed Web of Science ®Google Scholar
• Kwon JH, Kim I, Lee YG, et al. Clinical course of non-severe aplastic anemia in adults. Int J Hematol. 2010;91(5):770–775.
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R, Fefer A, et al. Aplastic anaemia treated by marrow transplantation. Lancet. 1972;1(7745):284–289.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Brand R, Oneto R, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy–The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37(1):69–80.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992;79(1):269–275.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Oneto R, Bruno B, et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol. 2000;103(1):19–25.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Passweg JR, Marsh JCW, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397–1400.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socié G, Schrezenmeier H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97(8):1142–1148.
   PubMed Web of Science ®Google Scholar
• Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007;109(10):4582–4585.
   PubMed Web of Science ®Google Scholar
• Champlin RE, Horowitz MM, Van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989;73(2):606–613.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Self S, Storb R, et al. Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. Blood. 1986;68(6):1363–1368.
   PubMed Web of Science ®Google Scholar
• Storb R, Champlin RE. Bone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant. 1991;8(2):69–72.
   PubMed Web of Science ®Google Scholar
• May WS, Sensenbrenner LL, Burns WH, et al. BMT for severe aplastic anemia using cyclosporine. Bone Marrow Transplant. 1993;11(6):459–464.
   PubMed Web of Science ®Google Scholar
• Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011;118(8):2351–2357.
   PubMed Web of Science ®Google Scholar
• Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol. 2012;157(3):339–346.
   PubMed Web of Science ®Google Scholar
• Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.
   PubMed Web of Science ®Google Scholar
• Aljurf M, Al-Zahrani H, Van Lint MT, et al. Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor. Bone Marrow Transplant. 2013;48(2):178–179.
   PubMed Web of Science ®Google Scholar
• Eapen M, Ramsay NK, Mertens AC, et al. Late outcomes after bone marrow transplant for aplastic anaemia. Br J Haematol. 2000;111(3):754–760.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee K-H, Yoon -S-S, et al. Allogeneic hematopoietic stem cell transplant for adults over 40 years old with acquired aplastic anemia. Biol Blood Marrow Transplant. 2012;18(10):1500–1508.
   PubMed Web of Science ®Google Scholar
• Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010;95(12):2119–2125.
   PubMed Web of Science ®Google Scholar
• Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171(4):585–594.
   PubMed Web of Science ®Google Scholar
• Miao M, Zhang X, Xu T, et al. Haploidentical hematopoietic stem cell transplantation for acquired severe aplastic anemia. Blood. 2015;126(23):3227–3227.
   Google Scholar
• Xu L-P, Jin S, Wang S-Q, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
   PubMed Web of Science ®Google Scholar
• Im HJ, Koh KN, Choi ES, et al. Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant. 2013;19(5):754–759.
   PubMed Web of Science ®Google Scholar
• Yagasaki H, Kojima S, Yabe H, et al. Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. Biol Blood Marrow Transplant. 2009;15(12):1603–1608.
   PubMed Web of Science ®Google Scholar
• Kuwatsuka Y, Kanda J, Yamazaki H, et al. A Comparison of Outcomes for Cord Blood Transplantation and Unrelated Bone Marrow Transplantation in Adult Aplastic Anemia. Biol Blood Marrow Transplant. 2016;22(10):1836–1843.
   PubMed Web of Science ®Google Scholar
• Socié G, Rosenfeld S, Frickhofen N, et al. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37(1):91–101.
   PubMed Web of Science ®Google Scholar
• Speck B, Gluckman E, Haak HL, et al. Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet. 1977;2(8049):1145–1148.
   PubMed Web of Science ®Google Scholar
• Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med. 1983;308(3):113–118.
   PubMed Web of Science ®Google Scholar
• Marsh J, Hows JM, Bryett KA, et al. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood. 1987;70(4):1046–1052.
   PubMed Web of Science ®Google Scholar
• Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991;324(19):1297–1304.
   PubMed Web of Science ®Google Scholar
• Rosenfeld S, Kimball J, Vining D, et al. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85(11):3058–3065.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Chaple M, Hows J, et al. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br J Haematol. 1993;83(1):145–151.
   PubMed Web of Science ®Google Scholar
• Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119(4):1075–1082.
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–19.
   PubMed Web of Science ®Google Scholar
• Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818–1825.
   PubMed Web of Science ®Google Scholar
• Kadia T, Ravandi F, Daver N, et al. Single-center experience of immunosuppressive therapy with or without eltrombopag in patients with aplastic anemia. Blood. 2015;126(23):4779–4779.
   Google Scholar
• Townsley DM, Dumitriu B, Young NS. Bone marrow failure and the telomeropathies. Blood. 2014;124(18):2775–2783.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Wu C, et al. Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol. 2006;133(6):606–611.
   PubMed Web of Science ®Google Scholar
• Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet (London, England). 2000;356(9241):1554–1559.
   PubMed Web of Science ®Google Scholar
• Zhang F, Zhang L, Jing L, et al. High-dose cyclophosphamide compared with antithymocyte globulin for treatment of acquired severe aplastic anemia. Exp Hematol. 2013;41(4):328–334.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Townsley D, Dumitriu B, et al. Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Blood. 2014;124(18):2820–2823.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?. Haematologica. 2009;94(3):310–312.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Marin P, Raghavachar A, et al. Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. Br J Haematol. 1993;85(2):371–377.
   PubMed Web of Science ®Google Scholar
• Means RT Jr., Krantz SB, Dessypris EN, et al. Re-treatment of aplastic anemia with antithymocyte globulin or antilymphocyte serum. Am J Med. 1988;84(4):678–682.
   PubMed Web of Science ®Google Scholar
• Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999;107(2):330–334.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Young NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;133(6):622–627.
   PubMed Web of Science ®Google Scholar
• Wei J, Huang Z, Guo J, et al. Porcine antilymphocyte globulin (p-ALG) plus cyclosporine A (CsA) treatment in acquired severe aplastic anemia: a retrospective multicenter analysis. Ann Hematol. 2015;94(6):955–962.
   PubMed Web of Science ®Google Scholar
• Stein RS, Means RT, Krantz SB, et al. Treatment of aplastic anemia with an investigational antilymphocyte serum prepared in rabbits. Am J Med Sci. 1994;308(6):338–343.
   PubMed Web of Science ®Google Scholar
• Marsh J, Schrezenmeier H, Marin P, et al. Prospective Randomized Multicenter Study Comparing Cyclosporin Alone Versus the Combination of Antithymocyte Globulin and Cyclosporin for Treatment of Patients With Nonsevere Aplastic Anemia: A Report From the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood. 1999;93(7):2191–2195.
   PubMed Web of Science ®Google Scholar
• Sloand EM, Olnes MJ, Weinstein B, et al. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica. 2010;95(3):382–387.
   PubMed Web of Science ®Google Scholar
• Gómez-Almaguer D, Jaime-Pérez JC, Garza-Rodríguez V, et al. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol. 2010;89(3):299–303.
   PubMed Web of Science ®Google Scholar
• Scheinberg P, Nunez O, Weinstein B, et al. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood. 2012;119(2):345–354.
   PubMed Web of Science ®Google Scholar
• Kim H, Min YJ, Baek JH, et al. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res. 2009;33(2):222–231.
   PubMed Web of Science ®Google Scholar
• Podesta M, Piaggio G, Frassoni F, et al. The assessment of the hematopoietic reservoir after immunosuppressive therapy or bone marrow transplantation in severe aplastic anemia. Blood. 1998;91(6):1959–1965.
   PubMed Web of Science ®Google Scholar